
|Articles|January 13, 2010
A randomised trial of bevacizumab and reduced light dose photodynamic therapy in age-related macular degeneration: The VIA study
Combination bevacizumab and 25?J/cm2 or 12?J/cm2 PDT significantly reduced the number of bevacizumab treatments required over six months. This study aimed at examining number of treatments, but not visual acuities. However, visual acuities responded favourably in all three groups.
Advertisement
British Journal of Ophthalmology - To determine if reduced light dose photodynamic therapy (PDT) combined with bevacizumab will decrease the number of bevacizumab treatments required over six months compared to bevacizumab monotherapy in neovascular age-related macular degeneration (AMD).
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times Europe
1
IGS 2026: Navigating MIGS and other modern glaucoma procedures
2
IGS 2026: The expanding role of artificial intelligence in ophthalmology
3
IGS 2026: Considering OCT in neuro-ophthalmology and neurological diseases
4
IGS 2026: Population-based normative data could transform AI in glaucoma
5



























